Our Story
Vivoryon Therapeutics has an experienced discovery and development team with a strong track record in delivering therapies to patients. We have product-candidates in both clinical and preclinical development and are focusing on age-related diseases with unmet medical need.
We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines.
Our Strategy
Identify and rapidly develop product candidates with clear biology, validated mechanisms and the potential to deliver life-changing improvement to patients suffering from age-related diseases.
first-in-class clinical phase 2 molecule in Alzheimer’s disease
clinical phase 1/2 ready first-in-class molecule for cancer immune checkpoint inhibition
patent families around QPCT and QPCTL inhibitors
track-record of bringing drugs from research into clinic
in vivo characterized small molecule inhibitors for cancer immune checkpoint inhibition
family of diabetes blockbuster drugs based on our research